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Niemann-Pick type C disease is a rare neurodegenerative disorder mainly caused by muta-
tions in NPC1, resulting in abnormal late endosomal/lysosomal lipid storage. Although
microgliosis is a prominent pathological feature, direct consequences of NPC1 loss on
microglial function remain not fully characterized. We discovered pathological proteomic
signatures and phenotypes in NPC1-deficient murine models and demonstrate a cell auton-
omous function of NPC1 in microglia. Loss of NPC1 triggers enhanced phagocytic uptake and
impaired myelin turnover in microglia that precede neuronal death. Npc1−/− microglia feature
a striking accumulation of multivesicular bodies and impaired trafficking of lipids to lyso-
somes while lysosomal degradation function remains preserved. Molecular and functional
defects were also detected in blood-derived macrophages of NPC patients that provide a
potential tool for monitoring disease. Our study underscores an essential cell autonomous
role for NPC1 in immune cells and implies microglial therapeutic potential.
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N iemann-Pick type C (NPC) disease is a rare lipid storagedisorder (LSD) with heterogeneous presentations,including neurological, systemic and psychiatric symp-
toms. NPC patients suffer from ataxia, supranuclear saccade and
gaze palsy and epileptic seizures due to progressive neurodegen-
eration, leading to premature death1–3. Psychiatric symptoms
comprise bipolar disorder, schizophrenia-like psychosis or major
depression4. NPC mainly manifests during childhood, although
juvenile and adult cases have also been reported1,3–6. Approxi-
mately 95% of the patients carry autosomal recessive mutations in
the NPC1 gene, with the remaining cases being caused by
mutations in the NPC23. The NPC1 gene encodes for a trans-
membrane protein and the NPC2 for a soluble protein that are
jointly responsible for the egress and recycling of lipoprotein-
derived cholesterol from late endosomes/lysosomes toward other
cell compartments like the endoplasmic reticulum (ER) or plasma
membrane7–9. Impairment of this lipid trafficking route causes an
abnormal accumulation of unesterified cholesterol and other
lipids (e.g., glycosphingolipids, sphingomyelin, and sphingosine)
in late endosomal/lysosomal compartments, resulting in endo-
somal/lysosomal dysfunction10,11.
A mouse model that carries a spontaneous loss of function
mutation within the Npc1 gene (deletion of 11 out of its 13
transmembrane domains, BALB/cNctr-Npc1m1N/J, further
abbreviated as Npc1−/−)12,13 reliably features early-onset human
pathology, including neurodegeneration of vulnerable NPC
regions, such as Purkinje cells in the cerebellum or other neurons
in the thalamus14,15. The cortex and hippocampus appear less
affected in NPC16. Behavioral defects, such as mild cerebellar
ataxia and tremor, can be detected in Npc1−/− mice at 6 weeks of
age and become more prominent by 8 weeks. Severe ataxia, dif-
ficulties in food and water uptake and weight loss appear by 10-12
weeks of age (humane endpoint)17.
The molecular mechanism responsible for neuronal death in NPC
is still not fully understood. It has been proposed that accumulation
of lipids, particularly sphingosine, can induce an imbalance in cal-
cium homeostasis and affect lysosomal trafficking18. Additionally,
lipid accumulation within lysosomes and mitochondrial membranes
may induce oxidative stress19,20. Different studies linked NPC1
dysfunction to alterations in mammalian target of rapamycin
complex 1 (mTORC1) and microtubule-associated proteins 1A/1B
light chain 3B (LC3) signaling, suggesting that autophagy might be
compromised in NPC21–25. Although peripheral organs such as liver
and spleen are affected by the disease, restoring NPC1 function in
the central nervous system (CNS) only prevents neurodegeneration
and premature lethality of the Npc1−/−mouse26. However, restoring
Npc1 expression in neurons only does not fully rescue the phenotype
and still results in lethality, suggesting that NPC1 is functionally
important in other brain cells as well27–30. Noteworthy, the Npc1
gene is ubiquitously expressed throughout the brain31, with parti-
cularly high expression in oligodendrocytes and microglia32.
Accordingly, it was shown that NPC1 function is crucial for correct
maturation of oligodendrocyte progenitor cells (OPCs) and the
maintenance of the existing myelin33,34.
Microglia, as the resident immune cells of the CNS, regulate
brain homeostasis by orchestrating essential physiological pro-
cesses like myelination and synaptogenesis35, but also actively
contribute to pathophysiology of neurodegenerative disorders36–41.
Gene expression studies including Alzheimer’s disease (AD),
amyotrophic lateral sclerosis, fronto-temporal lobar degeneration
or multiple sclerosis have underscored microglial diversity and
delineated homeostatic and disease signatures, often assigned as
“microglial neurodegenerative phenotype“ or “disease-associated
microglia” (DAM)36–38,42–46. Loss of Npc1 is also associated with
a massive microgliosis47–49, and alterations of transcriptomic
signatures were reported in microglia isolated from symptomatic
Npc1−/− mice50. However, as microglial pathology can be trig-
gered by neurodegenerative environment and consequences of a
specific loss of NPC1 in microglia have not been reported, it is
still debated whether microglial activation plays a causative role
in NPC pathology and merits therapeutic investigation11,50–53.
Although beneficial effects of reducing microglial activation were
reported17,50,54, cell culture experiments suggested that Npc1−/−
microglia do not directly trigger neurotoxicity55 and microglial
ablation in an NPC murine model was not beneficial52. Never-
theless, significant changes in inflammatory markers were
reported in both pre-symptomatic murine model and NPC
patients, suggesting that immune response could be a precocious
phenomenon preceding neuronal loss47,48,56–58. Taking together
the fundamental contribution of microglia during brain devel-
opment and pronounced NPC pathology at childhood age, early
microglial dysregulation could have profound pathological con-
sequences. Thus, deciphering microglial contribution to NPC
neuropathology is of key importance to judge whether modula-
tion of the inflammatory response bears therapeutic potential.
In the present study, we demonstrated that loss of NPC1 can
lock microglia in a disease state, largely compromising their
physiological functions. Additionally, we characterized a
cholesterol-triggered lipid trafficking defect in Npc1−/− microglia
and discovered that accumulation of undigested lipid material is
rather a consequence of impaired trafficking to lysosomes, as
lysosomal proteolytic function remains preserved. Furthermore,
we demonstrated that macrophages of NPC patients recapitulate
major molecular and functional defects observed in the brain
microglia, and thus present a valuable model for biomarker stu-
dies and clinical monitoring. Our study underscores an essential
cell autonomous role for NPC1 in microglia and implies their
therapeutic potential.
Results
Loss of NPC1 induces cholesterol storage in microglia and
triggers disease associated proteomic and functional sig-
natures. Symptomatic Npc1−/− mice (8 weeks) display a severe
degeneration in the cerebellum, particularly affecting the Purkinje
cell layer which was visualized by Calbindin immunostaining
(Supplementary Fig. 1a), as already reported14,15. Increased
immunoreactivity of a myeloid-specific lysosomal marker CD68
(Supplementary Fig. 1a) revealed microglial cells with amoeboid
morphology50, suggesting their active phagocytic status59–61.
However, regions like cortex (Supplementary Fig. 1b) and hip-
pocampus (Supplementary Fig. 1c) also showed pronounced
CD68 immunoreactivity in symptomatic Npc1−/− mice, but
without detectable alterations of neuronal marker NeuN, thus
excluding overt neuronal loss.
It is known that Npc1 is highly expressed in microglia32,
implicating a cell autonomous function in immune cells. To test
this hypothesis, we isolated primary cerebral microglia from
symptomatic Npc1−/− mice and cultured them in vitro. Using the
cholesterol binding dye Filipin62, we found increased intracellular
cholesterol content in Npc1−/− microglia compared to WT
(Fig. 1a). Co-staining with CD68 showed that most of the
cholesterol load in Npc1−/− microglia was localized within late
endosomes/lysosomes. Thus, cultured Npc1−/− microglia isolated
from the neurodegenerative brain environment still display a
cholesterol storage phenotype as reported55. This result suggests
that, in addition to neurons, NPC1 likely exerts a cell autonomous
function also in microglia and microglial phenotype should not
be considered only as a bystander of neurodegeneration28,53.
Findings in AD models revealed that under pathological
conditions microglia can switch from a resting homeostatic to a
DAM state that is characterized by distinct transcriptomic
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signatures37,63. We profiled the proteome of cerebral microglia
acutely isolated from 8 weeks old Npc1−/− and WT mice using
mass spectrometry (MS). Quality control of microglia enriched
fraction was performed via western blot analysis using specific
markers for microglia (Iba1), neurons (Tuj1), astrocytes (GFAP)
and oligodendrocytes (CNPase) (Supplementary Fig. 1d). Pro-
teomic profiles of microglia isolated from 8 weeks old mice
revealed major differences between Npc1−/− and WT, featuring
disease associated signatures (Fig. 1b, Supplementary Data 1)37,38.
Among significantly upregulated proteins, we identified TREM2,
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TYROBP, APOE, ITGAX/CD11c and many late endosomal/
lysosomal proteins, including LAMP1/2, LIPA, CD68, CTSB,
CTSD or GRN. Among those, ITGAX showed the largest increase
(39-fold). Concomitantly, markers associated with the homeo-
static microglial function like P2RY12, TMEM119, CSF1R,
CX3CR1, TGFB1 or TGFBR1 were decreased (Fig. 1b, Supple-
mentary Data 1). Notably, Ingenuity Pathway Analysis (IPA) of
MS data revealed phagosome maturation and autophagy as the
two pathways mostly affected by the loss of NPC1 (Fig. 1c,
Supplementary Fig. 2a), implicating a functional role of NPC1 in
regulation of intracellular trafficking in microglia. Moreover, we
compared our proteomic signatures with published transcriptome
data of Npc1−/− microglia50 and found a good correlation of
DAM and homeostatic signatures, suggesting their transcriptional
mode of regulation (Supplementary Fig. 2b). Western blot
analysis of selected DAM signature proteins (Fig. 1d) confirmed
our MS data. Of note, increased levels of lysosomal proteins such
as CTSB or CTSD in Npc1−/− microglia were not accompanied
by their reduced maturation as visualized by the increased levels
of pro, single and heavy chain forms, suggesting that lysosomal
degradation function, necessary for cathepsin maturation, is
preserved upon loss of NPC1 (Fig. 1d).
To study the functional consequences of altered microglial
proteomic signatures, we used an ex vivo amyloid β (Aβ) plaque
clearance assay64–66. To this end, microglial phagocytic clearance
of Aβ plaques was determined by measuring the reduction of
fibrillar Aβ load visualized by Thiazine Red (ThR) staining after
incubation of amyloid plaque bearing brain section with
exogenously added microglia (Fig. 1e). Microglia from 8-weeks
old Npc1−/− mice showed a 1.6-fold higher phagocytic clearance
of amyloid aggregates compared to WT cells (Fig. 1f), suggesting
that lysosomal degradation in Npc1−/− microglia is functional.
Taken together, our data show that a prominent neuroin-
flammation in Npc1−/− symptomatic mice is molecularly
characterized by altered microglial proteomic signatures of
intracellular trafficking, lysosomal function, and phagocytosis
and functionally reflected by increased phagocytic clearance.
Early changes in microglial Npc1−/− proteomic signatures
occur prior to neuronal death and correlate with increased
phagocytosis. Lack of NPC1 is likely to affect microglial
function already during developmental stages when microglia
are critically required for clearance of neuronal debris, synaptic
pruning, and successful myelination that are pre-requisites for
proper neuronal connectivity. To this end, we analyzed
microglial phenotype at pre-symptomatic stages of Npc1−/−
mice (P7). In agreement with the previous studies15,16,47,
Calbindin immunostaining delineated an intact layer of Pur-
kinje cells, whereas cerebellar CD68 immunoreactivity was
already upregulated in Npc1−/− microglia when compared to
WT (Fig. 2a). This result implicates that despite the preserved
neuronal environment, cerebellar Npc1−/− microglia were
already activated at pre-symptomatic stages. Importantly, we
also detected higher CD68 levels in less affected Npc1−/−
regions, including cortex (Fig. 2b), similarly as shown for the
symptomatic stages (Supplementary Fig. 1b and c).
To pinpoint early microglial molecular alterations, we analyzed
the proteome of cerebral microglia from pre-symptomatic Npc1−/−
animals. Although MS analysis of acutely isolated microglia from
P7 Npc1−/− mice showed less pronounced changes (Fig. 2c,
Supplementary Data 2) compared to the 8-weeks old Npc1−/−
microglia (Fig. 1b, Supplementary Data 1), most of the late
endosomal/lysosomal markers, including LAMP1/2, LIPA, CD63,
CD68, CTSB, CTSD or GRN were already significantly upregu-
lated. Upregulation of late endosomal/lysosomal proteins endorses
microglial state switch as an early event in the NPC neuropatho-
logical cascade. Similar to the symptomatic stage, canonical
pathway analysis of microglia from pre-symptomatic stages
highlighted autophagy and phagosome maturation as the two
most significantly altered pathways (Fig. 2d, Supplementary
Fig. 2c). Moreover, the prediction of upstream regulator activity
revealed signaling aberrations in Npc1−/− microglia, including the
most prominent downregulation or upregulation in pathways
regulated by TGFB1 and TFEB, respectively (Supplementary
Fig. 2d). Further analysis of proteins regulated by TGFB1 is
pinpointing alterations of endosomal/lysosomal signaling and
reduced microglial homeostasis in Npc1−/− animals at both
pathological stages (Supplementary Fig. 2e). Selected proteins
found upregulated in the proteomic analysis of pre-symptomatic
Npc1−/− mice were confirmed via western blot analysis (Fig. 2e).
One of the most significantly changed proteins at the pre-
symptomatic stage was the late endosomal and exosomal marker
Fig. 1 Loss of NPC1 induces microglial molecular and functional changes in symptomatic Npc1−/− mice. a Immunocytochemistry of cultured primary
microglia. Microglia were analyzed from three independent experiments (n= 3). Cholesterol was visualized using Filipin (blue). Npc1−/− cells show
increased Filipin levels compared to WT, demonstrating cholesterol accumulation. Boxed regions are enlarged in right panels and show cholesterol
accumulation within CD68 positive compartments (red) of Npc1−/− microglia. Scale bars: 25 μm. b Proteome analysis of acutely isolated microglia from 8-
weeks old WT and Npc1−/− littermates reveals significantly decreased homeostatic and increased DAM markers in Npc1−/− microglia. The negative log10
transformed p-value of each protein is plotted against its average log2 transformed LFQ ratio between Npc1−/− and WT microglia. The hyperbolic curves
indicate the threshold for a permutation-based FDR correction for multiple hypotheses. Significantly changed proteins (p-value less than 0.05 and FDR
corrected) with a log2 fold change larger than 0.5, or smaller than −0.5 are encircled in black (regulated), not regulated proteins are encircled in gray and
selected homeostatic (downregulated) and DAM (upregulated) proteins are highlighted in blue and in red, respectively. Microglia were analyzed from
three independent experiments (n= 3). c Phagosome maturation and autophagy are the most affected pathways upon NPC1 loss of function. The heatmap
shows the average log2 transformed LFQ ratio between WT and Npc1−/− microglia from significantly regulated proteins involved in phagosome maturation
and autophagy according to IPA. d Validation of MS data via western blot analysis and corresponding quantification. Representative immunoblots of
acutely isolated WT and Npc1−/− microglia show increased levels of DAM proteins (NPC2, LAMP1, CTSB, CTSD, CD68, CD63, GRN, TREM2, and APOE).
Calnexin was used as loading control. For cathepsins: p= pro-form; sc= single chain form; hc= heavy chain form. Proteins were quantified by
densitometry (ImageJ—NIH). At least three independent experiments were performed. Values were normalized on WT control and represent mean ± SEM
(unpaired two-tailed Student’s t-test). NPC1 (n= 4, p= 5.5 × 10−8); NPC2 (n= 3, p= 0.011); LAMP1 (n= 4, p= 0.0019); CTSB (n= 3, p= 5 × 10−4);
CTSD (n= 3, p= 0.08); CD68 (n= 4, p= 6 × 10−4); CD63 (n= 4, p= 1.5 × 10−6); GRN (n= 3, p= 0.003); TREM2 (n= 3, p= 0.015); APOE (n= 3, p=
0.068). e Representative images of WT and Npc1−/− microglia plated onto APPPS1 cryosection. Microglial lysosomes were visualized with an antibody
against CD68 (green), while Aβ plaques were detected with Thiazine Red (ThR) that stains fibrillar Aβ (red). Hoechst was used for nuclear staining (blue).
Scale bar: 25 μm. f Quantification of Aβ plaque clearance was performed by comparing ThR positive area between a brain section incubated with microglia
and the consecutive brain section where no cells were added. Values are expressed as percentages of amyloid plaque clearance normalized to the WT and
represent mean ± SEM from three independent experiments (n= 3, p= 0.039, unpaired two-tailed Student’s t-test).
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CD63 (Fig. 2c and e), which suggests that defects in endosomal/
lysosomal trafficking and sorting may be among the earliest
pathological alterations in Npc1−/− microglia67,68. Of note, CD63
was also increased at symptomatic stage, but as it could only
be detected in Npc1−/− microglia it is not listed in the
Supplementary Data 1.
Next, we tested whether proteomic fingerprint alterations were
accompanied by functional changes in microglia. To this end, we
performed the ex vivo Aβ plaque clearance assay. Microglia from
pre-symptomatic Npc1−/− mice showed more than 2.5-fold
increased phagocytic clearance compared to WT microglia
(Fig. 2f). To further confirm that lysosomal function is preserved
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in pre-symptomatic Npc1−/− microglia, we performed an in vitro
pulse/chase epidermal growth factor receptor (EGFR) degrada-
tion assay. Western blot analysis and its densitometry quantifica-
tion (Supplementary Fig. 3a and b) revealed comparable EGFR
degradation rate in Npc1−/− and WT microglia, confirming that
lysosomal degradation in microglia is not impaired by Npc1
deletion. Thus, our data demonstrate that molecular and
functional alterations of microglia are among the earliest
pathological hallmarks in NPC that occur independently from
the neuronal loss observed at later stages.
Cell autonomous function of NPC1 in microglia. To demon-
strate a cell autonomous mechanism for microglial activation in
NPC, we crossed a mouse line with a floxed allele of the Npc1
gene (C57BL/6-Npc1tm1.2Apl)69 with a mouse line expressing
Cre recombinase under myeloid specific Cx3cr1 promoter (B6.
Cx3cr1tm1.1(cre)Jung/N)70, thus generating a specific depletion
of NPC1 in microglia in double transgenic mice (Npc1flox/cre+).
Correspondingly, microglia enriched fraction isolated from 8-
weeks old Npc1flox/cre+ mice showed a complete loss of NPC1 and
a pronounced increase of late endosomal/lysosomal markers
including LAMP1, CD68, and CD63 when compared to microglia
enriched fraction of control mice (Npc1flox/cre−) (Fig. 3a). These
changes, triggered by the loss of NPC1 only in microglia, strongly
support its role in late endosomal/lysosomal pathway and switch
toward DAM signature that we described using the global
Npc1−/− model. Accordingly, histological analysis showed that,
despite an absence of neurodegeneration in all brain areas,
including Purkinje cell layer, CD68 reactivity was significantly
increased in cerebellum and cortex of Npc1flox/cre+ compared to
Npc1flox/cre− mice (Fig. 3b and c). Importantly, proteomic ana-
lysis of acutely isolated microglia from 5 months old Npc1flox/cre+
mice revealed a fully established DAM signature (Fig. 3d, Sup-
plementary Data 3), strongly resembling disease signatures we
observed in symptomatic Npc1−/− mice (Supplementary Fig. 3c).
These data confirm that NPC1 has a cell autonomous role in
microglia and that chronic inflammation which is triggered by its
loss is a key feature of NPC neuropathology that should be
considered for therapeutic targeting.
Npc1−/− microglia display enhanced uptake but impaired
turnover of myelin. It has been shown that Npc1−/− mice exhibit
reduced myelination71,72 that has been linked to impairments in
oligodendrocyte development33,34,73,74. However, it is well
appreciated that microglia engulf and clear myelin debris, reg-
ulating thereby myelin turnover75. This process can be impaired
by cholesterol accumulation in microglia76. To compare myelin
levels in the Npc1−/− and WT brain sections, we used a co-
staining for a myelin protein (2′,3′-cyclic-nucleotide 3′-phos-
phodiesterase, CNPase) and compact myelin (Fluoromyelin).
Symptomatic Npc1−/− mice showed reduced levels of both
CNPase and Fluoromyelin compared to WT (Fig. 4a). Next, we
analyzed removal of myelin debris by Npc1−/− microglia. We
found that in cerebellum (Fig. 4b) and cortex (Fig. 4c) of symp-
tomatic Npc1−/− mice almost all CD68 positive cells accumulated
Fluoromyelin intracellularly. Similarly, myelin accumulation was
also detected within microglia of symptomatic Npc1nmf164 mice52.
Noteworthy, we also observed colocalization between CD68 and
myelin marker CNPase in Npc1flox/cre+ mouse brain in contrast
to Npc1flox/cre− control (Fig. 4d), suggesting that loss of NPC1 in
microglia is sufficient to trigger increased myelin uptake.
Importantly, our proteomic analysis identified increased levels of
myelin-specific proteins (e.g., proteolipid protein 1, PLP1) and
proteins involved in microglial phagocytosis of myelin (e.g.,
galectin 3/LGALS3) in both Npc1−/− (Fig. 2c, Supplementary
Data 1 and 2) and Npc1flox/cre+ microglia (Fig. 3d, Supplementary
Data 3). Increased levels of PLP1 in microglia were also con-
firmed by western blot analysis (Fig. 4e, Supplementary Fig. 4a).
Taken together, our analysis suggests that loss of NPC1 triggers
hyper-reactive microglia that accumulate myelin and display
prominent alterations of their proteomic signatures.
Increased levels of myelin proteins within Npc1−/− and
Npc1flox/cre+ microglia could reflect a higher uptake, but also
possible defects in myelin turnover, or both. To address this
question, we explored an ex vivo assay of myelin clearance and
observed higher uptake of myelin in microglia from Npc1−/− pre-
symptomatic mice, as visualized by the increased levels of
Fluoromyelin within CD68 positive cells compared to WT
controls (Supplementary Fig. 4b). Of note, increased myelin
uptake phenotype by microglia is in line with increased uptake of
Fig. 2 Switch in microglial proteomic signatures and increased phagocytosis occur already in pre-symptomatic Npc1−/− mice and precede neuronal
loss. a, b Immunostaining of cerebellum (a) and cortex (b) of P7 WT and Npc1−/− mice from three independent experiments (n= 3) using antibodies
against neuronal markers (green) Calbindin (Purkinje cells, cerebellum), NeuN (cortex) and lysosomal microglial marker CD68 (red) reveal no
neurodegeneration in Npc1−/− mice (10×, upper panels). In contrast, CD68 immunoreactivity showed activated Npc1−/− microglia with amoeboid
morphology already at this early pathological stage (100×, lower panels). Hoechst was used for nuclear staining (blue). Scale bars: 250 μm (10×, upper
panels) and 25 μm (100×, lower panels). c Proteome analysis of acutely isolated microglia from P7 WT and Npc1−/− littermates. The negative log10
transformed p-value of each protein is plotted against its average log2 transformed LFQ ratio between Npc1−/− and WT microglia. The hyperbolic curves
indicate the threshold for a permutation-based FDR correction for multiple hypotheses. Significantly changed proteins (p-value less than 0.05 and FDR
corrected) with a log2 fold change larger than 0.5, or smaller than −0.5 are encircled in black (regulated) and not regulated proteins are encircled in gray.
Selected DAM proteins (upregulated) are highlighted in red and the synaptic protein synaptophysin (SYP) and myelin protein (PLP1) in black (others).
Microglia were analyzed from three independent experiments (n= 3). d Npc1 deletion affects phagosome maturation and autophagy already at pre-
symptomatic phase. The heatmap shows the average log2 transformed LFQ ratio between Npc1−/− and WT microglia of all significantly regulated proteins
involved in phagosome maturation and autophagy according to IPA. e Validation of MS results via western blot analysis and corresponding quantification.
Representative immunoblots of acutely isolated microglia from WT mice and Npc1−/− littermates showing increased level of late endosomal/lysosomal
markers (NPC2, LAMP1, CTSB, CTSD, CD68, and CD63). Calnexin was used as a loading control. For cathepsins: p= pro-form; sc= single chain form;
hc= heavy chain form. Proteins were quantified by densitometry (ImageJ—NIH) from at least three independent experiments. Values were normalized on
WT control and represent mean ± SEM (unpaired two-tailed Student’s t-test). NPC1 (n= 4, p= 3 × 10−6); NPC2 (n= 3, p= 0.004); LAMP1 (n= 3, p=
0.006); CTSB (n= 3, p= 0.04); CTSD (n= 3, p= 0.006); CD68 (n= 3, p= 0.0058); CD63 (n= 4, p= 6 × 10−4). f Npc1−/− microglia from P7 mice
already show increased phagocytic capacity toward Aβ. Quantification of Aβ plaque clearance was performed by comparing ThR positive area between a
brain section incubated with microglia and the consecutive brain section where no cells were added. Values are expressed as percentages of amyloid
plaque clearance normalized to the WT and represent mean ± SEM from three independent experiments (n= 3, p= 0.0003, unpaired two-tailed Student’s
t-test).
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other substrates upon loss of NPC1, including Aβ plaques
(Figs. 1f, 2f), synaptic proteins like synaptophysin (SYP) (Figs. 2c,
3d, Supplementary Data 1, 2, and 3) or Hoechst positive nuclear
material (Supplementary Fig. 4c and d). Taken together, we
observed increased phagocytic uptake of various microglial
substrates upon loss of NPC1. In contrast to Aβ plaques that
were efficiently degraded, myelin accumulated within Npc1−/−
microglia (Supplementary Fig. 4b), suggesting possible impair-
ments in myelin turnover.
Next, we investigated the turnover of exogenously added
myelin in cultured Npc1−/− microglia isolated from pre-
symptomatic mice. Cultured microglia have been pulsed for 6 h
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with purified and fluorescently labeled myelin76, and myelin
turnover was monitored over 72 h (Fig. 5a). After 6 h, myelin was
mainly found inside CD68 positive late endosomal/lysosomal
compartments in both WT and Npc1−/− cells. At 48 h, most of
the fluorescent labeling in WT cells was confined within vesicles
outside of CD68 positive late endosomal/lysosomal compart-
ments (Fig. 5b). Immunostaining for the membrane marker
Perilipin 2 confirmed that these vesicles were lipid droplets,
cellular organelles specialized for lipid recycling and storage and
crucial for cell metabolism77 (Supplementary Fig. 5). In contrast
to WT cells, Npc1−/− microglia accumulated labeled myelin
within the late endosomal/lysosomal compartment, suggesting an
impairment in myelin turnover and recycling into lipid droplets
(Fig. 5b). Even after 72 h, Npc1−/− microglia still contained the
engulfed myelin within late endosomal/lysosomal compartment
and completely lacked fluorescently labeled lipid droplets (Fig. 5a),
demonstrating a severe impairment and not just a delay in the
myelin degradation process. To further confirm microglial
impairment in myelin processing in Npc1−/− microglia, cells
were analyzed for lipid droplet formation at 72 h using the
lipophilic dye Nile red78 (Fig. 5c). Imaging analysis confirmed the
presence of Nile red positive lipid droplets localized to the cell
periphery in WT microglia. Again, in Npc1−/− microglia, lipid
droplet staining could not be observed and Nile red visualized
accumulated myelin within late endosomes/lysosomes.
Myelin accumulates in late endosomes/multivesicular bodies in
Npc1−/− mice. To further characterize endosomal/lysosomal
defects, we performed an electron microscopy (EM) analysis of
acutely isolated microglia from pre-symptomatic Npc1−/− and
control WT mice. This analysis revealed pronounced accumula-
tion of late endosomes/multivesicular bodies (MVBs) within
Npc1−/− microglia (Fig. 6a and b (1)). Morphological analysis
showed that most of these vesicles contained undigested lipid
material (Fig. 6a and b (2)), further supporting that Npc1−/−
microglia hold an increased phagocytic capacity toward myelin,
but fail in its processing. Interestingly, in contrast to increased
numbers of MVBs, no obvious increase in numbers of lysosomes
(Fig. 6a) were observed in microglia by EM as it has been pre-
viously suggested in other brain cells23. This is in agreement with
preserved lysosomal degradation function and suggests that
myelin accumulates in late endosomes/MVBs and thus does not
reach lysosomes where it is normally processed. To demonstrate a
trafficking defect and myelin accumulation in late endosomes/
MVBs, rather than lysosomes, we performed a pulse/chase
experiment with primary microglia from pre-symptomatic
Npc1−/− mice (Fig. 6c). Microglial cells were fed with fluores-
cently labeled myelin for 15 min, and myelin trafficking was
followed over 1 h using fluorescently labeled CTX to visualize
endosomes and DQ-BSA to label lysosomes. Confocal micro-
scopy analysis revealed that in WT cells most of the phagocytosed
myelin reached lysosomal compartment after 1 h. In contrast,
myelin was poorly colocalizing with DQ-BSA in Npc1−/−
microglia (Fig. 6d). Taken together, despite the enhanced pha-
gocytic uptake by Npc1−/− microglia, lipid trafficking toward the
lysosomes was impaired, thus resulting in myelin accumulation in
late endosomes/MVBs and defects in lipid clearance.
Lowering cholesterol rescues lipid droplet formation and
reduces pathological signatures of Npc1−/− microglia. Many
different lipid alterations have been reported in NPC and it is
debated which lipid is causative for neuropathological defects10.
To gain mechanistic insights into lipid alterations that are cau-
sative for microglial phenotypes we identified, we first lowered
cholesterol due to the major regulatory effect of NPC1 on cho-
lesterol transport79. Addition of cholesterol-lowering drug
methyl-β-cyclodextrin (MβCD) partially restored lipid droplet
formation in Npc1−/− microglia (Fig. 7a). As already shown upon
in vivo treatment of Npc1−/− mice, MβCD is able to alter
microglial transcriptional signatures50, suggesting that it may
reverse excessive DAM response of Npc1−/− microglia. Thus, we
looked for the rescue of microglial homeostatic signatures by
analyzing levels of the homeostatic marker TGFB180 and DAM
marker CTSD in cultured microglia upon MβCD treatment.
MβCD treatment of Npc1−/− microglia associated with a pro-
nounced increase in levels of TGFB1 and, concomitantly,
decreased levels of CTSD, supporting its potential protective
effect on enhancing microglial homeostasis and reducing DAM
signatures (Fig. 7b). Of note, as already reported, cultured
microglia show altered transcriptomic signatures with reduced
homeostatic and increased inflammatory profiles80,81, mitigating
differences between Npc1−/− and WT microglia in the absence of
an additional challenge. This underscores the importance of
proteomic studies in acutely isolated microglia. Taken together,
these experiments suggest that cholesterol accumulation in
microglia may, at least partially, be responsible for microglial
functional deficits and suggest the beneficial effect of cholesterol-
lowering drugs on reducing microglial activation.
Macrophages from NPC patients feature murine NPC1-
deficient microglial phenotypes. Npc1−/− and Npc1flox/cre+
Fig. 3 Cell autonomous function of NPC1 in microglia. a Western blot analysis and corresponding quantification of 8-weeks old Npc1flox/cre+ (Cre+) mice
with specific depletion of NPC1 in microglia and their littermate controls Npc1flox/cre− (Cre−). Representative immunoblots showing specific NPC1 depletion
in microglia enriched (MG enriched) compared to microglia depleted (MG depleted) fraction of Cre+ microglia. Increased levels of late endosomal/
lysosomal markers (LAMP1, CD68, and CD63) could only be detected in MG enriched fraction of Cre+ microglia. GAPDH was used as a loading control.
Microglia enriched fraction from three independent experiments was quantified by densitometry (ImageJ—NIH). Values were normalized on Cre− control
and represent mean ± SEM (unpaired two-tailed Student’s t-test). NPC1 (n= 3, p= 6 × 10−10); LAMP1 (n= 3, p= 3 × 10−4); CD68 (n= 3, p= 2 × 10−4);
CD63 (n= 3, p= 0.0097). b, c Immunostaining of cerebellum (b) and cortex (c) from 8-weeks old Npc1flox/cre+ (Cre+) and Npc1flox/cre− (Cre-) mice from
three independent experiments (n= 3) using antibodies against neuronal markers (green) Calbindin (Purkinje cells, cerebellum) and NeuN (cortex) and
lysosomal microglial marker CD68 (red). No neurodegeneration was observed in any of the investigated brain regions of Cre+ mice (×10, upper panels). In
contrast, increased CD68 immunoreactivity and amoeboid morphology were observed (×150, lower panels). Hoechst was used for nuclear staining (blue).
Scale bars: 250 μm (×10, upper panels) and 10 μm (×150, lower panels). d Proteome analysis of acutely isolated microglia from 5 months old Npc1flox/cre+
(Cre+) and Npc1flox/cre− (Cre−) mice. The negative log10 transformed p-value of each protein is plotted against its average log2 transformed LFQ ratio
between Cre+ and Cre− microglia. The hyperbolic curves indicate the threshold for a permutation-based FDR correction for multiple hypotheses.
Significantly changed proteins (p-value less than 0.05 and FDR corrected) with a log2 fold change larger than 0.5, or smaller than −0.5 are encircled in
black (regulated) and not regulated proteins are encircled in gray. Selected homeostatic (downregulated) and DAM (upregulated) proteins are in addition
highlighted in blue and in red, respectively. Synaptic protein SYP and myelin proteins MBP and PLP1 are highlighted in black (others). Microglia were
analyzed from three independent experiments (n= 3).
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microglia offer potential for therapeutic intervention and bio-
marker studies, but translation of animal models to human
patients is limited due to the very small number of NPC patients
(estimated at 1:100,000 live births) and limited access to viable
human brain tissue82. As a compromise, we explored human
peripheral macrophages for their phenotypic alterations in NPC.
First, we performed a proteomic analysis of peripheral blood
monocyte-derived macrophages from 7 NPC patients and 3
healthy controls (Fig. 8a, Supplementary Data 4). Despite the
larger variability among the human samples, this analysis
revealed a tendency of increased levels of late endosomal/lyso-
somal and DAM proteins, including LAMP1/2, NPC2, ITGAX,
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CTSD, CTSB, APOE, GRN, and LIPA in NPC patient macro-
phages compared to healthy controls (Fig. 8a). Furthermore,
increased levels of NPC2, LAMP1, CTSD, CD68, and GRN could
be validated by western blot analysis (Fig. 8b). Thus, analysis of
mouse microglia and NPC patient macrophages shows partially
overlapping alterations in proteomic signatures upon loss of
NPC1 and reveals its critical role in regulating endosomal/lyso-
somal homeostasis of myeloid cells. Noteworthy, in contrast to
rodent Npc1−/− microglia that fully lack NPC1 (Fig. 1d), patient
macrophages have residual levels of NPC1 (Fig. 8b) that may
contribute to less prominent alterations in proteomic signatures.
Next, we functionally characterized patient macrophages using
our ex vivo Aβ plaque clearance assay. Despite patient variability,
NPC1-deficient human macrophages showed a tendency toward
higher amyloid plaque clearance capacity in comparison to
control cells, resembling phenotypic features of rodent Npc1−/−
microglia (Fig. 8c and d). To further translate our observations
from NPC1-deficient murine cells, we also performed the in vitro
myelin phagocytic assay using patient cells (Fig. 8e). As we
observed for the murine model, human NPC patient cells were
capable to efficiently uptake exogenously added myelin, as judged
by the intracellular fluorescent signal that could be detected in
control and patient cells. At 48 h, fluorescently labeled lipid
droplets were observed at the periphery in control cells. Similar to
murine Npc1−/− microglia, fluorescently labeled lipid droplets
could not be detected at the cell periphery of NPC patient cells,
suggesting that a trafficking defect may preclude myelin
degradation and recycling into lipid droplets.
In conclusion, our data show that NPC patient macrophages
recapitulate many of the key molecular and phenotypic features
of murine Npc1−/− microglia and thus represent a valuable tool
to identify biomarkers and monitor disease progression and
therapeutic interventions in NPC patients.
Discussion
Our study reveals pathological proteomic fingerprints of micro-
glia already in pre-symptomatic phase of NPC that associate with
enhanced microglial phagocytic uptake and impairment in lipid
trafficking, characterized by aberrant delivery of myelin into
lysosomes and its accumulation within MVBs. This results in
myelin turnover defects and severe impairment in lipid droplet
formation that are accompanied by pronounced microglial
inflammation and compromised function. Microglia are respon-
sible for the neuroinflammatory phenotype that occurs in brains
of Npc1−/− mice as infiltration of peripheral macrophages could
not be detected in this model50,53,83. However, the contribution of
microglial activation to neurodegeneration in NPC is still
debated28,47,52,55,57,58. We detected pronounced microglial
reactivity throughout cortex and hippocampus prior to neuronal
loss that complements previous reports47,50. Furthermore, our
molecular and functional characterization reveals microglial
dysfunction as an early pathological insult in NPC. Importantly,
we demonstrate a cell autonomous role of NPC1 in microglia as
loss of NPC1 function in microglia only is sufficient to trigger
microglial activation and pathological proteomic signatures.
Taken together, our data show that microglial alterations are early
neuropathological hallmarks of NPC that should be considered
for therapeutic targeting.
In contrast to in-depth studies of microglial transcriptomic
profiles across neurodegenerative diseases, microglial proteomic
signatures are less characterized. Recent transcriptomic studies
revealed upregulation of DAM signatures in Npc1−/− mice50,84
and overlap that we observe between transcriptomic and pro-
teomic profiles suggests a transcriptional mode of regulation for
the major DAM profiles in NPC, similarly as we described in
AD microglia63. So far, it is unclear how DAM signatures across
various neurodegenerative diseases reflect microglial function
and whether they are predictive of beneficial or detrimental
responses. Here, we demonstrate that DAM signatures correlate
with increased phagocytic uptake both in murine Npc1−/−
microglia and in human NPC macrophages. Similarly, in a LSD
caused by granulin loss of function (Grn−/−)42,85, DAM sig-
natures correlated with increased microglial phagocytosis86. In
contrast, microglial cells in AD acquire DAM signatures36,38,
but impaired phagocytic function has been reported59,87,88. We
recently delineated proteomic signatures of AD microglia and
discovered Microglial Aβ Response Proteins (MARPs) that
reflect microglial alterations triggered by Aβ accumulation63.
Although NPC and AD microglia share many of the key MARPs
(e.g., ITGAX, APOE, LGALS3, TREM2, CD68, and CD63), they
differ in phagocytic capacity toward Aβ. Thus, our data
strengthen the fundamental importance of combining molecular
fingerprint analysis with functional studies to identify molecular
targets that are predictive of microglial function and could be
explored for repair. NPC patients typically do not show amyloid
plaque deposition, but do have increased Aβ production89–92.
This was ascribed as a consequence of the limited life expectancy
of NPC patients, but it is also tempting to speculate that
increased phagocytic Aβ clearance in NPC may compensate for
the increased Aβ generation and thereby counteract amyloid
deposition.
Our proteomic profiles of acutely isolated Npc1−/− microglia
revealed significant upregulation of numerous late endosomal/
lysosomal proteins (e.g., LAMP1/2, CD63, CD68, CTSB, and
CTSD) already in pre-symptomatic mice. Moreover, we show
that specific deletion of Npc1 in microglia is sufficient to
Fig. 4 Microglial NPC1 loss of function triggers increased myelin uptake. a Tile scan of whole brain section from 8-weeks old WT and Npc1−/− mice from
three independent experiments (n= 3) immunostained using antibody against CNPase as a general myelin marker (green) and Fluoromyelin that visualizes
compact myelin (red). Hoechst was used for nuclear staining (blue). Significantly reduced myelin levels are observed in Npc1−/− cortex and hippocampus
as shown by reduced CNPase immunoreactivity (green arrowheads). Fluoromyelin also reveals reduced levels of myelin in Npc1−/− mouse compared to
WT control (red stars). Scale bar: 750 μm. b, c Microglia engulf myelin in symptomatic Npc1−/− mice. Immunohistological analysis demonstrates
Fluoromyelin (green) positive myelin debris inside of CD68 positive (red) late endosomal/lysosomal compartments in cerebellum (b) and cortex (c) of 8-
weeks old Npc1−/− compared to WT mice from three independent experiments (n= 3). Scale bars: 50 μm. d Immunohistological analysis showing myelin
marker CNPase (green) colocalizing with lysosomal marker CD68 (red) of Iba1 positive microglia (white) in cerebellum of 8-weeks old Npc1flox/cre+ (Cre+)
compared to Npc1flox/cre− (Cre−) mice from three independent experiments (n= 3). Hoechst was used for nuclear staining (blue). Scale bars: 10 μm.
e Western blot analysis and corresponding quantification of myelin-specific protein PLP1 in 8-weeks old Npc1flox/cre+ (Cre+) mice and their littermate
controls Npc1flox/cre− (Cre-). Representative immunoblots from Cre+ and Cre− mice showing PLP1 accumulation (*) occurring in MG enriched fraction of
Cre+ mice. Of note, PLP1 running behavior differs between MG enriched and MG depleted fraction and higher molecular weight of PLP1 can be detected in
MG enriched fraction. This effect may be attributed to the aggregation of myelin proteins reported in microglia75. GAPDH was used as a loading control.
PLP1 levels were quantified by densitometry (ImageJ—NIH) from three independent experiments. Values were normalized on Cre− control and represent
mean ± SEM (n= 3, p= 0.003, unpaired two-tailed Student’s t-test).
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convert microglia toward a DAM phenotype. Thus, our study
demonstrates that microglial activation is a direct consequence of
loss of NPC1 function in microglia and not just an immune
response mediated by degenerating brain environment. Impor-
tantly, our analysis of NPC patient macrophages revealed some of
the changes observed in murine NPC1-deficient microglia (e.g.,
increased levels of LAMP1/2, CD68, CTSD, GRN, APOE or
ITGAX), albeit to a lesser degree. This may be contributed by
different degrees of NPC1 reduction (full loss of NPC1 in mouse
model versus partial reduction in human cells), increased
experimental variability or intrinsic differences between microglia
and macrophages. Another limitation of our study is the
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Fig. 5 Npc1−/− microglia display impairment in myelin turnover. a, b In vitro myelin phagocytosis assay. Cultured primary microglia isolated from P7 mice
from three independent experiments (n= 3) were incubated with fluorescently labeled myelin (green) and analyzed at 24, 48, and 72 h. Microglial
lysosomes were stained with anti-CD68 antibody (red). Hoechst was used for nuclear staining (blue). a Both WT and Npc1−/− microglia showed efficient
myelin uptake at 6 h. At 24 h (lower left panels) fluorescent labeling could be found within CD68 positive late endosomal/lysosomal compartments in both
WT and Npc1−/− microglia. At 48 h (upper right panels and higher magnification images shown in b), fluorescently labeled lipid vesicles were observed in
WT microglia, indicating myelin turnover. In contrast, Npc1−/− microglia accumulated myelin within the CD68 positive compartments and no fluorescently
labeled lipid vesicles were detected. At 72 h (lower right panels), in most of the WT cells myelin was degraded or signal could be detected in lipid vesicles.
In Npc1−/− microglia, myelin signal was still within the CD68 positive compartments, suggesting compromised myelin turnover. Scale bars: 25 μm.
c Primary microglia isolated from P7 WT and Npc1−/− mice from three independent experiments (n= 3) were fed with fluorescently labeled myelin
(green) and analyzed after 72 h. In order to confirm the identity of lipid vesicles forming as a result of myelin turnover, we stained microglia with Nile red
(red) to visualize lipid droplets. Boxed regions are enlarged in right panels and reveal co-localization between fluorescently labeled myelin vesicles and Nile
red, supporting myelin turnover and lipid droplet formation in WT microglia. In Npc1−/− microglia, Nile red mainly stained myelin deposits accumulating in
late endosomes/lysosomes, instead of lipid droplets at the cell periphery, confirming impairment in myelin turnover. Scale bars: 10 μm.
Fig. 6 Myelin accumulation in late endosomes/MVBs of Npc1−/− microglia. a EM analysis of microglia acutely isolated from pre-symptomatic WT and
Npc1−/− mice from three independent experiments (n= 3) shows the significant intracytoplasmic accumulation of MVBs in Npc1−/− cells. Boxed regions
are depicted at higher magnification in right panels (MVBs and lysosomes are pseudocolored in red and green, respectively). Scale bars: 2 μm (left panels)
and 1 μm (right panels). b Representative high magnification images of Npc1−/− cell shown in (a) (arrowheads 1 and 2) revealing accumulation of MVBs
(1). Undigested lipid material (lamellar structures) could be detected within MVBs (2). Scale bars: 0.2 μm. c Transport of phagocytosed myelin (green) was
followed over 1 h in P7 WT and Npc1−/− microglia from three independent experiments (n= 3) using DQ-BSA to visualize lysosomal compartments (red)
and fluorescently labeled cholera toxin (CTX, white) to visualize endocytic vesicles. Scale bar: 10 μm. d Quantification of the in vitro myelin transport assay
shows that, in contrast to WT control, phagocytosed myelin did not reach lysosomal compartments in Npc1−/− microglia. Values are expressed as
percentages of myelin signal colocalizing with DQ-BSA positive lysosomes and represent mean ± SEM from three independent experiments (n= 3, p=
0.0003, unpaired two-tailed Student’s t-test).
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treatment of recruited NPC patients with the approved drug
miglustat93. Differences in the length of treatment period and
patient-to-patient responsiveness could also contribute to repor-
ted proteomic profiles.
Noteworthy, and in line with our study, increased levels of
cathepsins were reported in brain and plasma of NPC
patients56,94. Along these lines, upregulation of pro-inflammatory
gene expression in both murine and human brains, as well as
inflammatory CSF signatures of NPC patients, suggest that
immune changes are early pathological hallmarks of NPC48.
Moreover, beside NPC, neuroinflammation is emerging as a
common pathological denominator in other LSDs, suggesting
that microglia are vulnerable to lysosomal impairments and that
neuroinflammation contributes to neuronal death95,96. These
findings are in line with our study showing that loss of NPC1
results in a strong pro-inflammatory phenotype and dysregulated
microglia at early pre-symptomatic disease stages. Accordingly,
pharmacological or genetic immune modulations have been
shown to be beneficial and improved life expectancy in NPC
murine models17,50,54.
Uncontrolled and overt microglial activation during early
Npc1−/− development can compromise physiological processes
and neuronal homeostasis. It is known that microglia play a role
in synaptic pruning97,98 and synaptic changes together with
axonal pathology are reported in Npc1−/− mice57,99. Of note,
increased uptake of neuronal material that we detect in Npc1−/−
microglia is in line with the previous reports50,100 and could
impair neuronal connectivity as described in AD, schizophrenia
and Grn−/− models101–104. Psychiatric symptoms are often found
in NPC patients, particularly in individuals with juvenile onset
disease, including mental retardation, behavioral problems,
schizophrenia-like psychosis, bipolar disorder, and attention
deficit hyperactivity disorder4,105. Further work is needed to
clarify whether excessive microglial activity we describe here may
compromise synaptic pruning and contribute to psychiatric
manifestations reported in NPC patients and this patho-
mechanism may be of relevance for other psychiatric disorders.
In addition to synaptic pruning, microglia orchestrate myelin
homeostasis, especially during development. Microglia control
OPC recruitment and differentiation106,107 and are responsible
Fig. 7 Lowering cholesterol in Npc1−/− microglia rescues lipid droplet phenotype. a MβCD treatment (48 h) of cultured Npc1−/− microglia isolated from
P7 mice and fed with fluorescently labeled myelin (green) partially restored the formation of lipid droplets as visualized by Nile red (red). Filipin dye (blue)
and an anti-CD68 antibody (white) were used to visualize cholesterol and late endosomal/lysosomal compartments, respectively. Scale bar: 10 μm. Cells
showing Nile red positive structures at cell periphery were quantified as lipid droplet positive cells. Three independent experiments were analyzed by
confocal microscopy (n= 3, p= 0.0003, one-way ANOVA followed by unpaired two-tailed Student’s t-test). b Western blot analysis and quantification of
TGFB1 and CTSD (p= pro-form; sc= single chain form; hc= heavy chain form) in cultured Npc1−/− and WT microglia isolated from P7 mice. At 5DIV,
Npc1−/− cells were treated with 250 µM MβCD for 48 h. GAPDH was used as a loading control. Protein levels were quantified by densitometry (ImageJ—
NIH) from four independent experiments. Values were normalized on WT control and represent mean ± SEM (one-way ANOVA followed by unpaired two-
tailed Student’s t-test). TGFB1 (n= 4, p= 0.02); CTSD (n= 4, p= 0.0002).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21428-5 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1158 | https://doi.org/10.1038/s41467-021-21428-5 | www.nature.com/naturecommunications 13
for the clearance of myelin debris. Impaired removal of myelin
debris by microglia can heavily compromise re-myelination upon
injury52,76. The hypomyelination phenotype described in NPC
mouse models and human patients has been mainly associated to
a cell autonomous impairment of oligodendrocytes33,34,71–73,108.
Our data reveal that at pre-symptomatic stage, when myelination
process just started109, Npc1−/− microglia already show increased
myelin uptake. Furthermore, LGALS3, that is expressed at high
levels in microglia, triggers OPC differentiation and, together
with TREM2, regulates myelin phagocytosis110. Our proteomic
dataset showed that LGALS3 abundance is strongly increased
both in Npc1−/− and Npc1flox/cre+ microglia, further supporting
higher phagocytic capacity toward myelin. Accordingly, early
accumulation of LGALS3 was found in blood serum of NPC
patients, suggesting its potential as a biomarker for therapeutic
monitoring56. Moreover, myelin accumulation and higher levels
of several myelin proteins (e.g., PLP1 and MBP) were detected in
Npc1flox/cre+ microglia in vivo. Thus, our data suggest a cell
autonomous defect in myelin turnover triggered by the loss of
NPC1 in microglia. This collective evidence suggests that, in
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addition to oligodendrocytes, hyperactive microglia may con-
tribute to aberrant myelination in NPC.
NPC1 loss of function has been associated with impairment in
lysosomal proteolysis25,52. However, the observed defects in
degradation of myelin in Npc1−/− microglia and NPC patient
macrophages are in contrast to what we observed for Aβ and
EGFR where endocytosed material was degraded efficiently,
supporting that lysosomal degradation function in myeloid cells
may be preserved upon loss of NPC1. Along these lines, preserved
lysosomal function has been anticipated in NPC patient
cells111,112. We hypothesize that myelin degradation is impaired
because phagocytosed material accumulates within late endo-
somes/MVBs that do not fuse with lysosomes. Impaired autop-
hagy, vesicular fusion, and MVB accumulation has been
demonstrated in NPC22,23,111–114. Protein substrates (e.g., Aβ or
EGFR) may follow an alternative route to reach the lysosome and
are therefore efficiently degraded, supporting our hypothesis of
preserved lysosomal degradation in microglia. Furthermore,
because the main lipid storage burden in NPC may not be
occurring in lysosomes, but rather in late endosomes/MVBs, the
term lysosomal storage disease may be revisited. Myelin accu-
mulation that we observed in Npc1−/− microglia may be occur-
ring in CD63 positive compartments, as this MVB/exosome
marker is the most significantly altered protein in Npc1−/−
microglia. CHM2A, that is another MVB protein, is also upre-
gulated in pre-symptomatic phase of NPC, strengthening the
relevance of MVB function for early pathogenesis of NPC115.
Lipids deriving from myelin degradation are normally stored in
lipid droplets that play a key regulatory function in cellular
metabolism77. Beyond their important metabolic role, lipid dro-
plets can also prevent lipo-toxicity116,117 or protect cells from
high reactive oxygen species (ROS)118–120, ER stress or mito-
chondrial damage77,121. Thus, tuning of lipid droplet cellular
content is a crucial physiological process since either disturbances
in formation119 or an excess of lipid droplets in microglia122 may
contribute to increased cellular stress and neurotoxicity.
Accordingly, increased ROS, cellular stress, and mitochondrial
dysfunction have been associated with NPC123. Moreover, aber-
rant lipid droplet formation124 may also be linked to autophagy
defects described in NPC21–24,111. It has been already shown that
low concentrations of cyclodextrin treatment mobilize cholesterol
from late endosomes/lysosomes and can delay neurodegeneration
in vivo125,126. Along these lines, our MβCD rescue experiment
provides a further mechanistic insight that lowering cholesterol
levels partially rescues lipid droplet formation and restores
homeostasis of Npc1−/− microglia, supporting the therapeutic
benefits of cholesterol lowering in NPC11,50. Our proteomic
analysis identified autophagosome formation and maturation as
the most affected pathway in microglia upon loss of NPC1. Sig-
nificant proteomic changes in proteins involved in autophagy
further strengthen the regulatory role of NPC1 in intracellular
trafficking22,23,111,112. Alterations in mTOR signaling were also
found in our macrophage proteome analysis, confirming that this
defect occurs in NPC patient cells.
The increased lipid burden in Npc1−/− microglia may con-
tribute to further upregulation of late endosomal/lysosomal
proteins in order to compensate for the lipid degradation failure.
This negative feedback loop likely results in enhanced phagocytic
uptake that further amplifies lipid burden and generates a chronic
and self-sustained microglial activation that may be harmful to
neurons. From a therapeutic point of view, we believe that a
pharmacological approach based on a combination of immune
modulation and lipid reducing agents should be considered as a
treatment strategy in NPC.
Methods
Animals. Male and female C57BL/6J (Jackson Laboratory stock N° 000664), BALB/
cNctr-Npc1m1N/J (Jackson Laboratory stock N° 003092)12,13, C57BL/6-
Npc1tm1.2Apl69, B6.Cx3cr1tm1.1(cre)Jung/N70 and APPPS1 mice127 were used in
this study. Animals were group housed under specific pathogen-free conditions.
Mice had access to water and standard mouse chow (Ssniff Ms-H, Ssniff Spe-
zialdiäten GmbH, Soest, Germany) ad libitum and were kept in a 12/12-h
light–dark cycle in IVC System at the temperature of 20–22 °C and humidity of 45-
46%. All experimental procedures were performed in accordance with the German
animal welfare law and approval for this work has been issued to DZNE by the
government of Upper Bavaria (license number ROB-55.2-2532.Vet_02-17-075).
Human material. All studies were performed in accordance with the 1964
Declaration of Helsinki and were approved by the local Ethics Committee of the
University of Munich. Seven clinically affected NPC1 mutation carriers and three
healthy volunteers (CTR) were included into this study. All participants gave
written informed consent prior to their inclusion in the study. Data including
NPC1 mutation status, pharmacological regimen and clinical features of partici-
pants included into the study are summarized in Supplementary Data 5.
Histology. Eight weeks old animals were transcardially perfused with 4% PFA/0.1
M PBS followed by 2 h post fixation with 4% PFA/0.1 M PBS. Postnatal day 7 (P7)
brains were fixed for 6 h in 4% PFA/0.1 M PBS. Free-floating 30 μm sagittal brain
sections were permeabilized and blocked for 1 h in PBS/0.5% Triton X-100/5%
normal goat serum (NGS). Next, samples were incubated O/N at 4 °C with primary
antibody solution in blocking buffer. After washing 3 times with PBS/0.2% Triton
X-100, corresponding goat secondary antibodies (Alexa Fluor, Invitrogen) were
diluted 1:500 in PBS/0.2% Triton X-100/2% NGS and incubated for 1 h at RT.
Nuclear staining (Hoechst 33342 1:2000, Invitrogen) or myelin dye (Fluoromyelin
Fig. 8 Human blood-derived macrophages from NPC patients resemble pathological alterations of murine Npc1−/− microglia. a Proteome analysis of
macrophages from 7 NPC patients (NPC) and 3 healthy controls (CTR). The negative log10 transformed p-value of each protein is plotted against its
average log2 transformed LFQ ratio between NPC and CTR macrophages. The hyperbolic curves indicate the threshold for a permutation-based FDR
correction for multiple hypotheses. Selected proteins altered in human NPC macrophages are highlighted in green and non-significantly changed proteins
are encircled in gray. b Validation of MS data via western blot analysis and corresponding quantification. Representative immunoblots from 3 NPC patients
and 3 healthy controls reveal increased levels of late endosomal/lysosomal proteins in NPC patient-derived macrophages. GAPDH was used as loading
control and quantification was performed by densitometry (ImageJ—NIH) from three independent experiments. Values were normalized on CTR and
represent mean ± SEM (unpaired two-tailed Student’s t-test). NPC1 (n= 3, p= 0.0003); NPC2 (n= 3, p= 0.02); LAMP1 (n= 3, p= 0.02); CTSD (n= 3,
0.01); CD68 (n= 3, p= 0.01); GRN (n= 3, p= 0.07). c Ex vivo Aβ plaque clearance assay. Representative immunostaining showing macrophages (CD45,
green) plated onto APPPS1 brain section that are clustering around and phagocytosing Aβ plaques, visualized with Thiazine Red (ThR, plaque core, red) and
3552 anti-Aβ antibody (Aβ plaque, white). Hoechst was used for nuclear staining (blue). Scale bar: 25 μm. d Quantification of phagocytosed Aβ plaques.
Values are expressed as percentages of amyloid plaque clearance normalized to CTR and represent mean ± SEM from 6 NPC patients and 3 healthy
controls (p= 0.19, unpaired two-tailed Student’s t-test). e In vitro myelin phagocytosis assay. Human macrophages from 2 NPC patients and 2 healthy
controls were fed with fluorescently labeled myelin (green) and analyzed after 48 h. Myeloid cells were visualized using an antibody against CD45 (red).
Hoechst was used as nuclear staining (blue). Boxed regions are enlarged in right panels and show that human CTR macrophages efficiently uptake and
turnover myelin as demonstrated by fluorescently labeled lipid droplets at the cell periphery. In contrast, we could not detect fluorescently labeled lipid
droplets at the cell periphery in NPC macrophages, suggesting trafficking defect that may preclude myelin turnover. Scale bars: 25 μm and 5 μm
(enlargements).
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red 1:300, Invitrogen) were incubated together with secondary antibodies. Sections
were washed twice with PBS/0.2% Triton X-100 and once with PBS before being
mounted using Fluoromount (Sigma Aldrich). Imaging was performed on 3 mice
per genotype and time point using a Leica SP5 confocal microscope. Primary
antibodies and dilutions were as follows: Calbindin (1:500, Swant); CD68 (1:500,
AbD Serotec); Iba1 (1:300, Wako); NeuN (1:500, Millipore); CNPase (1:300,
Abcam) and Synaptophysin (1:500, Abcam).
Primary microglia. After the brain had been dissected, cerebellum, olfactory bulb,
and brain stem were removed. The remaining cerebrum was dissociated using the
Neural Tissue Dissociation Kit (P) (Miltenyi Biotec) according to the manu-
facturer’s protocol. To positively select microglial cells, cell suspension was incu-
bated with CD11b microbeads (Miltenyi Biotec) and pulled down using a MACS
separation column (Miltenyi Biotec). Purity of microglial fraction was tested by
western blot using microglial, neuronal, astrocytic and oligodendrocyte markers as
described below (western blot analysis). For mass spectrometry analysis, microglial
fraction was washed twice with PBS and subsequently analyzed without culturing
(acutely isolated). For cell culture experiments, isolated microglia were resuspended
and plated at a density of 106 cells/6 cm dish in microglia culturing medium
containing DMEM/F12 (Gibco) supplemented with 10% fetal bovine serum (FBS,
Sigma Aldrich) and 1% PenStrep (Gibco). For adult microglia, medium was sup-
plemented with 10 ng/ml GM-CSF (R&D System). To analyze cholesterol load,
microglia from WT and Npc1−/− animals were plated onto glass coverslips and
cultured for 5 days in vitro (5DIV). Cells were fixed with 4% PFA/sucrose for 15
min at RT. After permeabilization with PBS/0.1% Triton X-100, cells were incu-
bated for 1 h in blocking solution (2% BSA/2% FBS/0.2% fish gelatin). Afterward,
primary antibody against CD68 (1:500, AbD Serotec) was incubated for 1 h at RT.
After washing, cells were incubated with a goat anti-rat Alexa Fluor secondary
antibody (1:500, Invitrogen) together with a cholesterol binding dye (Filipin
100 μg/ml, Sigma Aldrich)62 for 1 h at RT. Cells were washed, mounted using
Fluoromount and analyzed by confocal microscopy. Cells were analyzed from at
least three independent experiments. For MβCD treatment, both WT and Npc1−/−
P7 microglia were cultured at a density of 4 × 105 cells/well in a 12-well plate in
microglia culturing medium. At 5DIV, cells were treated with 250 µM MβCD
(Sigma Aldrich) or distilled water (Gibco) as a control for 48 h.
Isolation of peripheral blood monocyte-derived macrophages. Blood samples
(20 ml) from clinically affected homozygous NPC1 mutation carriers and healthy
donors were collected. Negative selection of peripheral blood monocyte-derived
macrophages was performed by incubating full blood for 20 min at RT with
RosetteSep Human Monocyte Enrichment Cocktail (StemCell Technologies). An
equal volume of washing buffer (D-PBS/2% FBS/1 mM EDTA) was added to each
sample and layer of macrophages was separated from red blood cells and plasma by
centrifugation on a Ficoll gradient (800 × g for 15 min, GE Healthcare). Potential
contamination by red cells was eliminated by incubating cell pellets with ACK lysis
buffer (Gibco) for 3 min at RT. Lysis buffer was quenched with 40 ml of washing
buffer and cells were centrifuged at 300 × g for 7 min. Cell pellets were resuspended
and plated in macrophage complete medium (RPMI 1640/10% FBS/1% PenStrep/
1X Pyruvate/1× NEAA) supplemented with 50 ng/ml hM-CSF (Thermo Scientific).
After 48 h, 50 ng/ml of fresh hM-CSF was re-added. At 5DIV, media was discarded
and adherent cells were washed once in PBS, incubated for 3 min at RT with
Versene (Lonza) and scraped in 5 ml macrophage complete medium for further
analysis.
Sample preparation for mass spectrometry. The microglia enriched fractions
(n= 3) or human macrophages (7 NPC patients and 3 healthy controls) were lysed
in 200 µl of STET lysis buffer (50 mM Tris/150 mM NaCl/2 mM EDTA/1% Triton
X-100, pH 7.5) as described before63,128 and incubated 15 min on ice with inter-
mediate vortexing. The samples were centrifuged for 5 min at 16,000 × g at 4 °C to
remove cell debris and undissolved material. The supernatant was transferred to a
fresh protein LoBind tube (Eppendorf) and the protein concentration was esti-
mated using the Pierce 660 nm protein assay (ThermoFisher Scientific). A protein
amount of 15 µg was subjected to tryptic protein digestion using the filter aided
sample preparation protocol (FASP)129 using Vivacon spin filters with a 30 kDa
cut-off (Sartorius). Briefly, proteins were reduced with 20 mM dithiothreitol and
free cysteine residues were alkylated with 50 mM iodoacetamide (Sigma Aldrich).
After the urea washing steps, proteins were digested with 0.3 µg LysC (Promega)
for 16 h at 37 °C followed by a second digestion step with 0.15 µg trypsin (Pro-
mega) for 4 h at 37 °C. The peptides were eluted into collection tubes and acidified
with formic acid (Sigma Aldrich). Afterward, proteolytic peptides were desalted by
stop and go extraction (STAGE) with self-packed C18 tips (Empore)130. After
vacuum centrifugation, peptides were dissolved in 2 µl 0.1% formic acid (Biosolve)
and indexed retention time peptides were added (iRT Kit, Biognosys).
LC-MS/MS analysis. For label-free protein quantification (LFQ), peptides were
analyzed on an Easy nLC 1000 or 1200 nanoHPLC (Thermo Scientific) which was
coupled online via a Nanospray Flex Ion Source (Thermo Scientific) equipped with
a PRSO-V1 column oven (Sonation) to a Q-Exactive HF mass spectrometer
(Thermo Scientific). An amount of 1.3 µg of peptides was separated on in-house
packed C18 columns (30 cm × 75 µm ID, ReproSil-Pur 120 C18-AQ, 1.9 µm, Dr.
Maisch GmbH) using a binary gradient of water (A) and acetonitrile (B) supple-
mented with 0.1% formic acid (0 min, 2% B; 3:30 min, 5% B; 137:30 min, 25% B;
168:30 min, 35% B; 182:30 min, 60% B) at 50 °C column temperature.
Data-dependent acquisition (DDA) was used for LFQ of microglia from
Npc1−/− mice and human macrophages. Full MS scans were acquired at a
resolution of 120,000 (m/z range: 300–1400; automatic gain control (AGC) target:
3E+6). The 15 most intense peptide ions per full MS scan were selected for peptide
fragmentation (resolution: 15,000; isolation width: 1.6m/z; AGC target: 1E+5;
normalized collision energy (NCE): 26%). A dynamic exclusion of 120s was used
for peptide fragmentation.
Data independent acquisition (DIA) was used for LFQ of microglia from
Npc1flox/cre mice. One scan cycle included a full MS scan (m/z range: 300–1400;
resolution: 120,000; AGC target: 5E+6 ions) and 30 MS/MS scans covering a range
of 300–1400m/z with consecutive m/z windows (resolution: 30,000; AGC target:
3E+6 ions). The maximum ion trapping time was set to “auto”. A stepped NCE of
26% ± 2.6% was used for fragmentation.
Mass spectrometry data analysis and LFQ. Proteome from Npc1−/− microglia
was analyzed with the software Maxquant, version 1.6.3.3 (maxquant.org, Max-
Planck Institute Munich)131. The MS data were searched against a reviewed
canonical fasta database of Mus musculus from UniProt (download: November the
5th 2018, 17,005 entries). Trypsin was defined as a protease. Two missed cleavages
were allowed for the database search. The option first search was used to recalibrate
the peptide masses within a window of 20 ppm. For the main search peptide and
peptide fragment mass tolerances were set to 4.5 and 20 ppm, respectively. Car-
bamidomethylation of cysteine was defined as static modification. Acetylation of
the protein N-terminal as well as oxidation of methionine were set as variable
modifications. The false discovery rate for both peptides and proteins was adjusted
to less than 1%. The “match between runs” option was enabled with a matching
window of 1.5 min. LFQ of proteins required at least one ratio count of unique
peptides. Only unique peptides were used for quantification. Normalization of LFQ
intensities was performed separately for the age groups because LC-MS/MS data
were acquired in different batches. The protein LFQ reports of Maxquant were
further processed in Perseus132. The protein LFQ intensities were log2 transformed
and log2 fold changes were calculated between NPC-deficient and WT samples
separately for the different age groups, mouse models and patients. LFQ intensities
were detected in every biological replicate in order for the proteins to be considered
quantifiable and no imputation was performed to replace missing values. An
unpaired Student’s t-test with two-tailed distribution was applied to evaluate the
significance of proteins with changed abundance. Additionally, a permutation-
based false discovery rate (FDR) estimation (threshold: FDR= 5%) was used to
perform multiple hypothesis correction133. To ensure the adequate FDR cutoff, we
experimentally determined the s0 values separately for each experimental dataset.
Briefly, the “relative difference” di of each protein was calculated, which includes s0
as a variable. Next, s0 was optimized separately for each experimental dataset,
based on an interpolation to reach the lowest coefficient of variation for the
absolute di values133. A log2 fold change larger than 0.5, or smaller than −0.5, a
p-value less than 0.05 and significant regulation after FDR filtering were defined as
regulation thresholds criteria.
The proteomic data was further analyzed through the use of ingenuity pathway
analysis (IPA, QIAGEN Inc., https://www.qiagenbioinformatics.com/products/
ingenuity-pathway-analysis). Standard settings were used for the analysis. Proteins
with a log2 fold-change larger than 0.5, or smaller than −0.5 and a p-value less
than 0.05 were defined as protein regulation thresholds.
Proteome from human macrophages was analyzed with Maxquant version
1.6.3.3 using the same settings searching against a reviewed fasta database of Homo
sapiens from UniProt including isoforms (download: December the 17th 2018,
42,432 entries).
Proteome from Npc1flox/cre microglia was analyzed with the software
Spectronaut (version 12.0.20491.14.21367) with standard settings using our
previously generated microglia spectral library, including 122,542 precursor ions
from 91,349 peptides, which represent 6223 protein groups63. Briefly, the FDR of
protein and peptide identifications was set to 1%. LFQ of proteins was performed
on peptide fragment ions and required at least one quantified peptide per protein.
Protein quantification was performed on at least 2 and maximum 3 peptides per
protein group. A permutation-based FDR correction for multiple hypotheses was
applied as described above.
Western blot analysis. Acutely isolated and cultured microglia or human mac-
rophages were lysed in STET lysis buffer supplemented with protease and phos-
phatase inhibitors (Sigma Aldrich). Lysate protein content was quantified using
Bradford assay (Biorad) according to the manufacturer´s protocol. At least 10 μg
per sample were separated on a bis-tris acrylamide gel followed by western blotting
either on a PVDF or nitrocellulose membrane (Millipore) using the following
antibodies: Iba1 (1:1000, Wako); GFAP (1:1000, Dako); Tuj1 (1:1000, Covance);
CNPase (1:1000, Abcam); NPC1 (1:1000, Abcam); NPC2 (1:1000, Sigma Aldrich);
LAMP1 (1:1000, Sigma Aldrich); Cathepsin B (1:2000, R&D System); Cathepsin D
(1:1000, Novus Biologicals); mouse CD68 (1:1000, AbD Serotec); human CD68
(1:500, Acris); mouse CD63 (1:1000, Abcam); mouse GRN (1:50, clone 8H10,85);
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human GRN (1:1000, Invitrogen); TREM2 (1:10, clone 5F466); APOE (1:1000,
Millipore); PLP1 (1:1000, Abcam); EGFR (1:1000, Abcam) and TGFB1 (1:1000,
R&D System). Blots were developed using horseradish peroxidase-conjugated
secondary antibodies (Promega) and the ECL chemiluminescence system (GE
Healthcare). An antibody against Calnexin (1:1000, Stressgen) or GAPDH (1:2000,
Abcam) was used as loading control. Blot densitometry quantification was per-
formed using gel analyzer tool in ImageJ (NIH) with at least n= 3 for both human
and murine samples.
Ex vivo Aβ plaque clearance and myelin phagocytic assay. To functionally
characterize myeloid cells (primary microglia and human macrophages), we
adapted a previously reported phagocytic assay64. Briefly, a 10 μm brain section
from an AD mouse model (APPPS1) was placed on a poly L-lysine coated glass
coverslip. In order to stimulate cell recruitment to the plaque site, brain sections
were incubated for 1 h at RT with an antibody against human Aβ (5 μg/ml 6E10,
BioLegend for microglia and 3 μg/ml 2D8134 for macrophages). Isolated cells were
plated at a density of 3 × 105 (microglia) or 2.5 × 105 (macrophages) cells/coverslip
and incubated either for 5DIV (microglia) or 1DIV (macrophages) in corre-
sponding culturing medium. Next, samples were fixed with a 4% PFA/sucrose
solution for 15 min at RT. Immunostainings were performed as described above
using an antibody against myeloid cells (anti-CD68 for microglia and anti-CD45
(1:300, Abcam) for macrophages) and Aβ plaque (1:500, 3552,63). Fibrillar Aβ
(plaque core) was visualized using Thiazine Red (ThR, 2 μM, Sigma Aldrich) added
into the secondary antibody solution. To evaluate the phagocytic capacity of
myeloid cells, plaque coverage (ThR signal area for microglia or 3552 for macro-
phages) was quantified, comparing brain section incubated with cells with a con-
secutive brain section where no cells were added. Quantification was done using a
macro tool in ImageJ (NIH), applying to 10×16-bit tail scan picture of the whole
coverslip with a threshold algorithm (OTSU) and measuring particles with a pixel
size from 5 to infinity. For microglia, each experimental group was tested in three
independent experiments, while for macrophages 6 NPC patients and 3 healthy
controls were analyzed.
Similarly, we applied this assay to evaluate the capability of P7 microglia to
uptake and digest myelin from the APPPS1 brain section. In order to evaluate
myelin level after incubation with microglia, we used Fluoromyelin dye (1:300,
Invitrogen) added together with the secondary antibody solution. CD68 was used
to visualize microglia. Each experimental group was tested in three independent
experiments.
In vitro myelin phagocytic assay. Myelin was isolated from 8-weeks old C57BL/
6J mouse brains which were homogenized by sonication in 10 mM HEPES/5
mM EDTA/0.3 M sucrose/protease inhibitors76. The homogenate was layered
on a gradient of 0.32 M and 0.85 M sucrose in 10 mM HEPES/5 mM EDTA (pH
7.4) and centrifuged at 75,000 × g for 30 min with a SW41 Ti rotor (Beckman
Coulter). The myelin fraction was isolated from the interface, and subjected to
three rounds of osmotic shock in sterile ultrapure water and centrifuged at
75,000 × g for 15 min. The resulting pellet was subjected to the same procedure
to obtain a pure myelin fraction. The yield of myelin was calculated by mea-
suring the total amount of protein with the Bradford assay (Biorad). For the
fluorescence labeling of myelin, a PKH67 Green Fluorescent Cell Linker Mini
Kit was used (Sigma Aldrich).
Primary microglia from P7 mice and human macrophages were isolated and
cultured as described above. Cells were fed with purified green fluorescently labeled
myelin at a concentration of 50 μg/ml. At 6 h, myelin was washed out and cells
were fixed at 24/48/72 h with a 4% PFA/sucrose solution for 15 min.
Immunostaining of fixed cells was performed as described above using antibodies
against CD68 and Perilipin 2 (1:200, Progen) for microglia and CD45 for patient
macrophages. Microglial lipid droplets were visualized using Nile red staining kit
(Abcam) according to the manufacturer’s protocol. In order to monitor myelin
trafficking during phagocytosis, primary P7 microglia were incubated with cholera
toxin (CTX) subunit B Alexa Fluor™ 647 Conjugate (0.5 μg/ml, Thermo Fisher
Scientific) and Red DQ-bovine serum albumin (DQ-BSA; 10 μg/ml, Invitrogen) for
30 min at 37 °C in microglial culturing medium. Cells were pulsed for 15 min with
green fluorescently labeled myelin (10 μg/ml) and fixed after 1 h. For microglia
rescue experiments, after myelin wash out, microglia were treated with 250 µM
MβCD (Sigma Aldrich) or with distilled water (Gibco) as a control for 48 h and
fixed with 4% PFA/sucrose for 15 min. For the quantification of the rescue
experiment, 300 cells per technical replicate were analyzed (three technical
replicates/cell preparation). Cells with Nile red positive structures in cell periphery
were defined as lipid droplet positive cells. MβCD cholesterol-reducing activity was
tested using a cholesterol-binding dye (Filipin 100 µg/ml, Sigma Aldrich). For all
microglia experiments, three independent cell preparations (n= 3) were treated
and analyzed by confocal microscopy. For human macrophages, cells from 2 NPC
patients and 2 healthy controls were analyzed.
EM analysis. The microglial pellet was preserved throughout all fixation, con-
trasting and infiltration steps. Cells were fixed for 30 min in 2% PFA/2.5% glu-
taraldehyde (EM-grade, Science Services) in 0.1 M sodium cacodylate buffer (pH
7.4) (Sigma Aldrich), washed three times in 0.1 M sodium cacodylate buffer before
postfixation in reduced osmium (1% osmium tetroxide (Science Services)/0.8%
potassium ferrocyanide (Sigma Aldrich) in 0.1 M sodium cacodylate buffer). After
contrasting in aqueous 0.5% uranylacetate (Science Services), the pellet was
dehydrated in an ascending ethanol series, infiltrated in epon (Serva) and cured for
48 h at 60 °C. Ultrathin sections (50 nm) were deposited onto formvar-coated
copper grids (Plano) and postcontrasted using 1% uranyl acetate in water and
ultrostain (Leica). Transmission Electron Microscopy micrographs were acquired
on a JEM 1400plus (JEOL) using the TEMCenter and tile scans with the Shot-
Meister software packages (JEOL), respectively. Three independent cell prepara-
tions were analyzed (n= 3).
EGFR degradation assay. Both WT and Npc1−/− P7 microglia were cultured at a
density of 5 × 105 cells/well in a 12-well plate in microglia culturing medium. At
5DIV, microglia culturing medium was replaced with serum-free medium, con-
taining only DMEM/F12 and 1% PenStrep. After 3 h of serum deprivation (t= 0),
cells were treated with mouse recombinant EGF (40 ng/ml, R&D System) and
cycloheximide (20 µg/ml, Sigma Aldrich) in serum-free medium. Cells were lysed
at different time points (0, 1, 3, and 6 h) after treatment in STET lysis buffer and
supplemented with protease and phosphatase inhibitors. EGF receptor (EGFR)
level in each lysate was analyzed via western blot using an antibody against EGFR
(anti-EGFR antibody EP38Y, Abcam). Each experimental group was tested in
microglia isolated from three independent experiments (n= 3).
Statistical analysis. For comparison between two groups, unpaired Student’s
t-test with two-tailed distribution was used. For the in vitro myelin phagocytic
assay with MβCD, one-way ANOVA followed by unpaired two-tailed Student’s t-
test was used. Data are represented as mean ± standard error of the mean (SEM). A
value of p < 0.05 was considered significant (*p < 0.05; **p < 0.01; ***p < 0.001).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
The mass spectrometry proteomics data are deposited at the ProteomeXchange
Consortium via the PRIDE partner repository with the dataset identifier PXD019447
(proteomic signature of Npc1−/− microglia), PXD019452 (proteomic signature of
Npc1flox/Cre microglia) and PXD020659 (proteomic signature of NPC human
macrophages). Source data are provided with this paper.
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